Long-term clinical follow up of patients suffering from moderate to severe COVID-19 infection: A monocentric prospective observational cohort study

In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was detected in Wuhan, China, and identified as the etiological agent of coronavirus disease 2019 (COVID-19). Clinical manifestations range from the absence of symptoms to acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure (1 –4). For most patients, the infection is mild with low-grade fever and cough, but 15% of patients experience respiratory impairment, combined with diffuse alveolar damage (DAD), pulmonary (hyper)inflammatory infiltrates and microvascular thrombosis associated to elevated levels of inflammatory mar kers, and require hospital care (3,5).

Source: International Journal of Infectious Diseases - July 14, 2021 Category: Infectious Diseases Authors: Gilles Darcis, Antoine Bouquegneau, Nathalie Maes, Marie thys, Monique Henket, Florence Labye, Anne-Fran çoise Rousseau, Perrine Canivet, Colin Desir, Doriane Calmes, Raphael Schils, Sophie De Worm, Philippe Léonard, Paul Meunier, Michel Moutschen, Rena Source Type: research